Table 1.
Baseline characteristics of study participants in the overall population. Values are numbers (percentages) unless stated otherwise
| Characteristic | LMWH (n=948) | LMWH+GCS (n=940) |
|---|---|---|
| Age (years) (mean (SD)) | 59.3 (15.2) | 58.1 (14.9) |
| Sex | ||
| Male | 347 (36.6) | 346 (36.8) |
| Female | 601 (63.4) | 594 (63.2) |
| Body mass index (mean (SD)) | 28.7 (5.9) | 29.0 (6.1) |
| VTE risk | ||
| Moderate (score 1) | 151 (15.9) | 150 (16.0) |
| High (score ≥2) | 797 (84.1) | 790 (84.0) |
| Bleeding risk | ||
| No bleeding risk | 918 (96.8) | 911 (96.9) |
| One or more risk factors | 30 (3.2) | 29 (3.1) |
| Caprini risk | ||
| Low (score 0-1) | 4 (0.4) | 5 (0.5) |
| Moderate (score 2) | 23 (2.4) | 28 (3.0) |
| High (score 3-4) | 275 (29.0) | 267 (28.4) |
| Highest (score ≥5) | 646 (68.1) | 640 (68.1) |
| EQ-5D-5L* (mean (SD)) | 0.825 (0.185) | 0.817 (0.192) |
| EQ-5D VAS† (mean (SD)) | 76.9 (17.5) | 77.0 (18.1) |
| Oral contraceptives (women only) | ||
| Yes | 16/601 (2.7) | 24/594 (4.0) |
| No | 584/601 (97.2) | 570/594 (96.0) |
| Missing | 1/601 (0.2) | 0/594 (0) |
| Hormone replacement therapy (women only) | ||
| Yes | 35/601 (5.8) | 39/594 (6.6) |
| No | 565/601 (94.0) | 555/594 (93.4) |
| Missing | 1/601 (0.2) | 0/594 (0) |
| History of malignancy | 213 (22.5) | 197 (21.0) |
EQ-5D-5L=EuroQol five dimensions five levels; EQ-5D VAS=EuroQol five dimensions visual analogue scale; GCS=graduated compression stockings; LMWH=low molecular weight heparin.
No significant differences existed between trial groups.
*
LMWH n=942; LMWH+GCS n=926.
†
LMWH n=941; LMWH+GCS n=923.